Deferred Tax Assets, Valuation Allowance of Quince Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Quince Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • Quince Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $91,488,000, a 7.5% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Quince Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $91,488,000 +$6,377,000 +7.5% 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q4 2023 $85,111,000 +$15,419,000 +22% 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q4 2022 $69,692,000 +$11,081,000 +19% 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q4 2021 $58,611,000 +$23,577,000 +67% 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q4 2020 $35,034,000 +$18,545,000 +112% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q4 2019 $16,489,000 +$8,549,000 +108% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q4 2018 $7,940,000 31 Dec 2018 10-K 16 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.